{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Dent S"],"pubmed_abstract":["<h4>Background</h4>Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer (mbc). This study reports clinical benefit and toxicities experienced by women with mbc treated with nab-paclitaxel at the Ottawa Hospital Cancer Centre.<h4>Methods</h4>Women with mbc treated with single-agent nab-paclitaxel between June 2006 and December 2010 were included in this analysis. Retrospective data obtained included demographics, disease characteristics, prior chemotherapy, nab-paclitaxel treatment, toxicity, and survival. Clinical benefit was defined as partial or complete response or stable disease (by clinical or radiologic evaluation, or both) at 6 months or more.<h4>Results</h4>Of 43 women (mean age: 57.0 years; range: 34-74 years), most had"],"journal":["Current oncology (Toronto, Ont.)"],"pagination":["24-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3557328"],"repository":["biostudies-literature"],"pubmed_title":["Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre."],"pmcid":["PMC3557328"],"pubmed_authors":["Hopkins S","Dent S","Fraser J","Graham N","Dranitsaris G","Campbell M"],"additional_accession":[]},"is_claimable":false,"name":"Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.","description":"<h4>Background</h4>Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer (mbc). This study reports clinical benefit and toxicities experienced by women with mbc treated with nab-paclitaxel at the Ottawa Hospital Cancer Centre.<h4>Methods</h4>Women with mbc treated with single-agent nab-paclitaxel between June 2006 and December 2010 were included in this analysis. Retrospective data obtained included demographics, disease characteristics, prior chemotherapy, nab-paclitaxel treatment, toxicity, and survival. Clinical benefit was defined as partial or complete response or stable disease (by clinical or radiologic evaluation, or both) at 6 months or more.<h4>Results</h4>Of 43 women (mean age: 57.0 years; range: 34-74 years), most had","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Feb","modification":"2025-06-01T00:11:05.756Z","creation":"2025-06-01T00:11:05.756Z"},"accession":"S-EPMC3557328","cross_references":{"pubmed":["23443761"],"doi":["10.3747/co.20.1202"]}}